What if the most dangerous part of brain tumor treatment isn't the surgery… but the wait that comes after it?

In this episode of Med Tech Gurus, we sit down with Dr. Michael Garcia, Chief Medical Officer and Head of Clinical Development at GT Medical Technologies, and one of the leading voices reshaping how we treat brain tumors. Dr. Garcia leads the clinical strategy behind GammaTile® — an implantable, bioabsorbable device that delivers targeted radiation from inside the brain immediately after surgery, eliminating the dangerous 3–6 week delay where tumors often begin to grow back.

Under his leadership, GT Medical has reported powerful interim clinical data showing GammaTile can reduce the risk of recurrence or death by more than 50% compared to standard of care — with no increase in safety concerns. Today, more than 150 leading cancer centers are using this technology, changing not only outcomes, but something equally important: patient experience. Less anxiety. Fewer treatment delays. Fewer logistical burdens. More hope.

Dr. Garcia shares the science, the strategy, and the deeply personal mission behind this innovation — along with insights on clinical trial design, multidisciplinary collaboration, and building medtech that truly serves patients. If you care about oncology, neurosurgery, innovation with purpose, or patient-centered design, this is a conversation you won't want to miss.